, Volume 3, Issue 3, pp 173-174
Date: 07 Oct 2012

Avasimibe

  • show all 0 hide
This is an excerpt from the content

Adis Comments

Avasimibe [CI 1011] is an ACAT inhibitor that was in development with Parke-Davis (Warner-Lambert) in the USA for the treatment of atherosclerosis and hyperlipidaemia.

This profile has been selected from R&D Insight™, a pharmaceutical intelligence database produced by Adis International Ltd.

In June 2000, Warner-Lambert merged with Pfizer and the resulting company retained the Pfizer name. Parke-Davis was integrated into Pfizer Global Research and Development.

Pfizer is continuing development and avasimibe is in Phase III studies. Over 1300 patients have been treated for up to 1 year and initial results from these studies were expected mid-2001. However, they have not been reported. Table I

Features and properties

Profile

Pharmacokinetics

The pharmacokinetics of avasimibe were examined in two placebo-controlled Phase I trials. In a single-dose study, healthy volunteers received single oral doses of avasimibe (12.5–500mg) in fasted or fed states. At dose levels of 12.5–125mg, ava